转移性三阴性乳腺癌中游离DNA肿瘤分数与体细胞拷贝数变异与生存的关联
这项回顾性队列研究对164例经活检证实的转移性三阴性乳腺癌患者进行血浆cfDNA低覆盖全基因组测序,无需预先知道肿瘤突变即可确定96.3%患者的肿瘤分数和63.9%患者的体细胞拷贝数变异。预设cfDNA肿瘤分数≥10%与显著更差的转移生存相关(中位6.4 vs 15.9个月),且独立于临床病理因素(HR 2.14,95%CI 1.4-3.8,P<.001)。
要点
- cfDNA肿瘤分数≥10%与转移性TNBC显著更差生存相关(中位6.4 vs 15.9个月)。
- 无需肿瘤突变知识即可从cfDNA确定大多数患者的肿瘤分数和SCNAs。
- 转移性TNBC中某些SCNAs富集且具预后意义,涉及NOTCH2、AKT2、AKT3等驱动基因。
核心结论
- cfDNA肿瘤分数≥10%与转移性TNBC显著更差生存独立相关。
- 转移性TNBC中特定SCNAs富集且具预后意义,对转移、耐药和新疗法有启示。
研究设计与样本
- 回顾性队列研究,纳入164例经活检证实的转移性TNBC患者,均接受过(新)辅助或转移阶段化疗。
- 对血浆cfDNA进行低覆盖全基因组测序,无需预先知道肿瘤突变。
主要发现
- 无需预先肿瘤突变知识,可确定96.3%患者的cfDNA肿瘤分数和63.9%患者的SCNAs。
- 转移性与原发性TNBC的拷贝数谱和基因组改变百分比高度相似。
- 转移性TNBC中某些SCNAs较配对原发瘤及TCGA和METABRIC原发TNBC更常见,包括NOTCH2、AKT2、AKT3的染色体获得。
- 预设cfDNA肿瘤分数≥10%与显著更差的转移生存相关(中位6.4 vs 15.9个月)。
- cfDNA肿瘤分数≥10%的预后意义独立于临床病理因素(HR 2.14;95%CI 1.4-3.8;P<.001)。
关键数值与推荐
- cfDNA肿瘤分数预设阈值为≥10%,与更差转移生存相关(中位6.4 vs 15.9个月)。
- 多因素分析中cfDNA肿瘤分数≥10%的HR为2.14(95%CI 1.4-3.8,P<.001)。
临床怎么用
- 可通过血浆cfDNA低覆盖全基因组测序无创评估转移性TNBC的肿瘤分数和SCNAs。
- cfDNA肿瘤分数≥10%可用于识别预后显著更差的转移性TNBC患者。
局限性
- 回顾性单中心研究,样本来自单一三级医疗机构。
- 仅63.9%患者可确定SCNAs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Cell-free DNA (cfDNA) offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and may be associated with patient prognosis. Triple-negative breast cancer (TNBC) is characterized by few mutations but extensive somatic copy number alterations (SCNAs), yet little is known regarding SCNAs in metastatic TNBC. We sought to evaluate SCNAs in metastatic TNBC exclusively via cfDNA and determine if cfDNA tumor fraction is associated with overall survival in metastatic TNBC. Patients and Methods In this retrospective cohort study, we identified 164 patients with biopsy-proven metastatic TNBC at a single tertiary care institution who received prior chemotherapy in the (neo)adjuvant or metastatic setting. We performed low-coverage genome-wide sequencing of cfDNA from plasma. Results Without prior knowledge of tumor mutations, we determined tumor fraction of cfDNA for 96.3% of patients and SCNAs for 63.9% of patients. Copy number profiles and percent genome altered were remarkably similar between metastatic and primary TNBCs. Certain SCNAs were more frequent in metastatic TNBCs relative to paired primary tumors and primary TNBCs in publicly available data sets The Cancer Genome Atlas and METABRIC, including chromosomal gains in drivers NOTCH2, AKT2, and AKT3. Prespecified cfDNA tumor fraction threshold of ≥ 10% was associated with significantly worse metastatic survival (median, 6.4 v 15.9 months) and remained significant independent of clinicopathologic factors (hazard ratio, 2.14; 95% CI, 1.4 to 3.8; P < .001). Conclusion We present the largest genomic characterization of metastatic TNBC to our knowledge, exclusively from cfDNA. Evaluation of cfDNA tumor fraction was feasible for nearly all patients, and tumor fraction ≥ 10% is associated with significantly worse survival in this large metastatic TNBC cohort. Specific SCNAs are enriched and prognostic in metastatic TNBC, with implications for metastasis, resistance, and novel therapeutic approaches.
引用
- Stover DG, Parsons HA, Ha G, et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018. PMID: 29298117. doi:10.1200/JCO.2017.76.0033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。